Table 1.

Anti-PD-1/PD-L1 agents currently approved for the treatment of advanced and locally advanced NSCLC

Drug	PD-L1 expression on tumor cells
Advanced, pretreated setting
Nivolumab1,2	Any (or unknown)
Pembrolizumab3	≥1%
Atezolizumab4	Any (or unknown)
Advanced, first-line setting
Pembrolizumab5	≥50%
Platin-pemetrexed and pembrolizumab7,8,a	Any (or unknown)
Locally advanced disease, after chemo-radiotherapy
Durvalumab6	Any (or unknown)

Note:

^aAt the time of this study, this combination had US FDA approval for the treatment of non-squamous histologies only. EMA approval was still underway.

Abbreviation: FDA, US Food and Drug Administration.